Collegium to Present New Real-World Data at PainConnect 2026

Rhea-AI Summary

Collegium (Nasdaq: COLL) will present two real-world data posters at PainConnect 2026, AAPM's annual meeting in Salt Lake City, March 5-8, 2026. The posters, presented March 6 on TV 1 at The Grand America Hotel, analyze buprenorphine real-world use and urine drug testing.

Presentations by Jody L. Green, PhD, highlight nonmedical use rates and presence of illicit drugs among patients treated with buprenorphine versus full agonist opioids. Important safety and approved-use information for BELBUCA (buprenorphine buccal film) is also included.

News Market Reaction – COLL

-5.88%

1 alert

-5.88% News Effect

On the day this news was published, COLL declined 5.88%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 5–8, 2026 Poster count: 2 posters Presentation date: Friday, March 6 +5 more

8 metrics

Conference dates March 5–8, 2026 PainConnect 2026 / AAPM Annual Meeting

Poster count 2 posters Real-world data from pain portfolio at PainConnect 2026

Presentation date Friday, March 6 Belbuca real-world data posters on TV 1

Time slot 10:00–10:05 AM Abstract #27 Belbuca nonmedical use analysis

Time slot 10:05–10:10 AM Abstract #28 Belbuca urine drug testing analysis

Abstract number Abstract #27 Rate and frequency of nonmedical use of buprenorphine vs other opioids

Abstract number Abstract #28 Presence of illicit drugs in urine tests among pain clinic patients

Market cap $1,264,122,930 Pre-news market capitalization for COLL

Market Reality Check

Price: $35.62 Vol: Volume 474,109 is above t...

normal vol

$35.62 Last Close

Volume Volume 474,109 is above the 20-day average of 378,134, indicating elevated trading interest ahead of the meeting. normal

Technical Shares at $39.61 are trading above the 200-day MA of $38.55 and about 22% below the 52-week high.

Peers on Argus

COLL slipped 0.95% while peers were mixed: PCRX and EVO showed gains, DVAX was r...

1 Down

COLL slipped 0.95% while peers were mixed: PCRX and EVO showed gains, DVAX was roughly flat, and AMPH and HROW were marginally lower. Only one peer (EVO) appeared in the momentum scanner, and it was flagged moving down, reinforcing a stock-specific move tied to company news rather than a broad sector rotation.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	ADHD awareness campaign	Positive	-3.9%	Launch of Paris Hilton-led ADHD awareness and Jornay PM campaign.
Mar 02	Investor conferences	Neutral	-0.2%	Announcement of participation in multiple March investor conferences.
Feb 26	Earnings release	Positive	-3.3%	Strong Q4 and FY 2025 results and reaffirmed 2026 guidance.
Feb 23	Community partnership	Neutral	-0.3%	Multi-year sponsorship of sensory rooms at multiple stadiums.
Feb 12	Earnings date notice	Neutral	+0.3%	Announcement of timing and webcast details for earnings call.

Pattern Detected

Recent positive or promotional news has often been met with short-term share price weakness, including after strong earnings.

Recent Company History

Over the past few weeks, Collegium reported strong Q4 and FY 2025 results with substantial revenue and EBITDA growth, yet the stock declined after the earnings release. Earlier, the company announced its upcoming earnings date and later filed the annual report, highlighting a diversified pain and ADHD portfolio and the Ironshore acquisition. More recently, Collegium focused on branding and community engagement through ADHD campaigns and stadium sensory room sponsorships. Today’s PainConnect real-world data presentation fits this pattern of portfolio- and awareness-focused communications.

Market Pulse Summary

The stock moved -5.9% in the session following this news. A negative reaction despite neutral, data-...

Analysis

The stock moved -5.9% in the session following this news. A negative reaction despite neutral, data-focused conference news would fit a pattern where shares have sometimes traded lower even after constructive updates, including strong earnings. Such a move could have reflected profit-taking, positioning, or sensitivity to broader regulatory and opioid-related risks rather than the specifics of the posters. Attention would then shift to upcoming investor conferences, future data releases, and any new regulatory filings that might influence sentiment.

Key Terms

buprenorphine, urine drug testing, benzodiazepines, central nervous system (CNS) depressants, +4 more

8 terms

buprenorphine medical

"Rate and Frequency of Nonmedical Use (NMU) of Buprenorphine Compared to Other Opioids"

A medication used to treat opioid dependence and certain types of pain that works by easing cravings and withdrawal without producing the full high of stronger opioids. Think of it like a dimmer switch that turns down opioid effects instead of shutting them off, helping people stabilize. For investors, buprenorphine matters because regulatory approvals, prescribing rules, patents, competition and pricing directly affect sales, product value and the financial outlook for companies that make or sell it.

urine drug testing medical

"Presence of Illicit Drugs in Urine Drug Testing Among Pain Clinic Patients"

Urine drug testing is a laboratory analysis of a urine sample to detect the presence of recreational or prescription drugs and their breakdown products. Investors watch it because test results affect regulatory compliance, hiring and workplace safety, eligibility for clinical trials, and demand for testing products and treatment services; think of it as a smoke detector for drug exposure that can trigger costs, legal risks, or new revenue for companies.

benzodiazepines medical

"Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants"

A class of prescription drugs that calm the brain and nervous system, commonly used to treat anxiety, insomnia, and seizures; they act like a dimmer switch that reduces overactive mental or physical responses. Investors care because benzodiazepines shape demand for certain drug makers, influence regulatory and safety scrutiny, affect prescription trends and patent lifecycles, and can drive liability, pricing and market-share shifts in the pharmaceutical and healthcare sectors.

central nervous system (CNS) depressants medical

"with benzodiazepines or other central nervous system (CNS) depressants, including alcohol"

Central nervous system (CNS) depressants are drugs that slow down brain and nerve activity, similar to turning down a dimmer switch that reduces the speed of thinking, movement, and breathing. For investors, they matter because their safety, effectiveness, and potential for misuse drive regulatory approvals, prescribing limits, legal risks, and market demand—factors that can sharply affect sales, development costs, and company valuations in pharmaceuticals and healthcare.

neonatal opioid withdrawal syndrome medical

"risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening"

Neonatal opioid withdrawal syndrome is a condition in which a newborn baby shows withdrawal symptoms after being exposed to opioids before birth; symptoms can include fussiness, poor feeding, tremors, breathing problems and difficulty sleeping. For investors, it matters because rising cases drive demand for hospital care, specialized treatments, diagnostic tests and follow-up services, influence regulatory scrutiny and reimbursement policies, and can affect companies developing therapies, monitoring tools or related healthcare services — like how increased traffic raises demand for road maintenance.

opioid analgesic risk evaluation and mitigation strategy (REMS) regulatory

"Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)"

A Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics is a regulatory safety program required by the U.S. Food and Drug Administration to reduce the chance of addiction, misuse, and overdose while allowing legitimate pain treatment. It works like a safety plan—requiring special training for prescribers, patient education and sometimes restricted distribution—so investors should view it as a factor that can limit prescribing, add compliance costs, and affect a drug’s commercial reach and liability profile.

naloxone medical

"Ask your healthcare provider about medicines like naloxone or nalmefene"

Naloxone is a fast-acting medication that temporarily reverses the life-threatening effects of opioid overdose by blocking opioids’ effects on the brain, like an emergency master key that unlocks someone from a dangerous drug-induced shutdown. It matters to investors because demand, pricing, regulatory approvals, product formulations (injectable, nasal spray), and government purchasing programs can drive sales, affect company valuations, and influence litigation and public-health-related revenue streams.

nalmefene medical

"Ask your healthcare provider about medicines like naloxone or nalmefene"

Nalmefene is a prescription medication that blocks specific brain receptors to counteract the effects of opioids and to reduce the craving and rewarding effects of heavy drinking in people with dependence. Think of it as a circuit breaker that interrupts the brain signals driving overdose or compulsive alcohol use; for investors it matters because clinical results, regulatory approvals, patent protection and market adoption determine its potential revenue and competitive value in addiction treatment markets.

AI-generated analysis. Not financial advice.

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium’s pain portfolio and reflect the Company’s continued focus on generating evidence that helps inform everyday practice.

“Understanding how therapies perform in real-world settings is essential to informing pain treatment,” said Thomas Smith, M.D., Chief Medical Officer. “These analyses contribute important context that can inform clinical practice and ongoing scientific dialogue.”

The poster presentations will take place Friday, March 6, on TV 1 at The Grand America Hotel.

BELBUCA®
Time	TV	Abstract Title	Presenter
10:00 – 10:05 AM	1	Abstract #27: Rate and Frequency of Nonmedical Use (NMU) of Buprenorphine Compared to Other Opioids for the Treatment of Pain	Jody L. Green, PhD
10:05 – 10:10 AM	1	Abstract #28: Presence of Illicit Drugs in Urine Drug Testing Among Pain Clinic Patients Treated with Buprenorphine or Full Agonist Opioids	Jody L. Green, PhD

APPROVED USE
BELBUCA® (buprenorphine buccal film) CIII is:
• A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine when other pain medicines do not treat your pain well enough or you cannot tolerate them.
• A long-acting opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.
• Not to be taken on an “as needed” basis.

IMPORTANT SAFETY INFORMATION about BELBUCA®

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA

Addiction, Abuse, and Misuse

Because the use of Belbuca exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Belbuca, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Belbuca are essential. Misuse or abuse of Belbuca by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death.

Accidental Exposure

Accidental exposure of even one dose of Belbuca, especially in children, can result in a fatal overdose of buprenorphine.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Belbuca and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.

Important information about BELBUCA:

• Get emergency help or call 911 right away if you take too much BELBUCA (overdose). When you first start taking BELBUCA, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Ask your healthcare provider about medicines like naloxone or nalmefene that can be used in an emergency to reverse an opioid overdose.
• Taking BELBUCA with other opioid medicines, benzodiazepines, gabapentinioids (gabapentin or pregabalin), alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.
• Never give anyone else your BELBUCA. They could die from taking it. Selling or giving away BELBUCA is against the law.
• Store BELBUCA securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.

Do not use BELBUCA if you have:

• severe asthma, trouble breathing, or other lung problems.
• a bowel blockage or have narrowing of the stomach or intestines.

Before taking BELBUCA, tell your healthcare provider if you have a history of:

• head injury, seizures
• heart rhythm problems (long QT syndrome)
• liver, kidney, thyroid problems
• pancreas or gallbladder problems
• problems urinating
• tooth problems, including a history of cavities
• abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems
  

Tell your healthcare provider if you are:

• noticing your pain getting worse. If your pain gets worse after you take BELBUCA, do not take more of BELBUCA without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking BELBUCA.
• pregnant or planning to become pregnant. Use of BELBUCA for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening I not recognized and treated.
• breastfeeding. Not recommended during treatment with BELBUCA. It may harm your baby.
• living in a household where there are small children or someone who has abused street or prescription drugs.
• taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking BELBUCA with certain other medicines can cause serious side effects and could lead to death.
  

When taking BELBUCA:

• Do not change your dose. Apply BELBUCA exactly as prescribed by your healthcare provider. Use the lowest effective dose possible for the shortest time needed.
• See the detailed Instructions for Use for information about how to apply BELBUCA.
• Do not apply BELBUCA if the package seal is broken or the film is cut, damaged, or changed in any way.
• After the film has adhered to your cheek, avoid eating or drinking until the film has completely dissolved, usually within 30 minutes.
• After BELBUCA is completely dissolved, rinse your mouth with water and swallow. Wait for at least one hour before brushing teeth.
• Report any problems with your teeth immediately to your healthcare provider and schedule an appointment with a dentist. Tell your dentist that you have started taking BELBUCA. Avoid touching or moving the buccal film with your tongue or fingers.
• Do not chew, swallow, snort or inject BELBUCA. This will result in uncontrolled delivery of buprenorphine and may cause you to overdose and die.
• Call your healthcare provider if the dose you are using does not control your pain.
• Do not stop using BELBUCA without talking to your healthcare provider.
• Dispose of expired, unwanted, or unused BELBUCA by removing the BELBUCA film from the foil packaging, and promptly flushing down the toilet (if a drug takeback option is not readily available). Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

While using BELBUCA DO NOT:

• Drive or operate heavy machinery, until you know how BELBUCA affects you. BELBUCA can make you sleepy, dizzy, or lightheaded.
• Drink alcohol or use prescription or over-the-counter medicines containing alcohol. Using products containing alcohol during treatment with BELBUCA may cause you to overdose and die.

The possible side effects of BELBUCA are:

• nausea, constipation, headache, vomiting, dizziness, and sleepiness. Call your healthcare provider if you have any of these symptoms and they are severe.
  

Get emergency medical help or call 911 right away if you have:

• trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.
  

These are not all the possible side effects of BELBUCA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.

Please see full Prescribing Information, including Boxed Warning on Addiction, Abuse, and Misuse, and other serious risks, and Medication Guide or speak to your healthcare provider if you have questions about BELBUCA.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business. Collegium’s strategy includes growing its commercial portfolio, with ADHD as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our 2026 financial guidance, including projected product revenues, adjusted operating expenses and adjusted EBITDA, statements related to the projected launch of the authorized generic versions of Nucynta and Nucynta ER and anticipated shared net profits following the launch of such authorized generic versions, statements related to current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contacts:
Ian Karp
Vice President, Investor Relations
ir@collegiumpharma.com

Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

FAQ

What will Collegium (COLL) present at PainConnect 2026 and when?

Collegium will present two real-world data posters on March 6, 2026 at PainConnect 2026. According to the company, presentations occur on TV 1 at The Grand America Hotel and summarize clinical insights from its pain medication portfolio to inform practice.

What topics do Collegium's (COLL) March 6 posters cover at PainConnect 2026?

The posters cover nonmedical use of buprenorphine and illicit drugs in urine testing among pain clinic patients. According to the company, the research compares buprenorphine-treated patients to those on full agonist opioids using real-world clinical data.

Who is presenting Collegium's (COLL) posters at PainConnect 2026?

Jody L. Green, PhD, is listed as the presenter for both relevant abstracts on March 6. According to the company, Dr. Green will present Abstract #27 and Abstract #28 focusing on buprenorphine real-world analyses.

Where and how can investors view Collegium's (COLL) PainConnect 2026 presentations?

Presentations are scheduled on TV 1 at The Grand America Hotel on March 6, 2026 during AAPM PainConnect. According to the company, attendees can view the posters in person at the meeting in Salt Lake City, Utah.

Does the PainConnect 2026 announcement mention BELBUCA safety information for COLL investors?

Yes; the announcement reiterates BELBUCA approved use and boxed warnings about addiction and respiratory depression. According to the company, important prescribing and safety guidance accompanies the poster disclosures for context on product risk.

Will Collegium's (COLL) PainConnect 2026 posters change clinical practice immediately?

The company presents real-world evidence meant to inform practice, not immediate guideline changes. According to the company, the analyses provide clinical context and contribute to scientific dialogue that may influence practice over time.